ArticleCancer prevention research (Philadelphia, Pa.)2021
Weight Loss During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-Stage Cancer of The Endometrium.
Article in Cancer prevention research (Philadelphia, Pa.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.The Cochrane database of systematic reviews · 2025Pooled it
- Gynaecological cancer surveillance for women with Lynch syndrome: systematic review and cost-effectiveness evaluation.Health technology assessment (Winchester, England) · 2024Pooled it
- Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.BMC medicine · 2022Pooled it
- Adherence and weight loss with a total diet replacement programme for increased cancer risk associated with obesity: a UK cohort study.BMJ open · 2026Article
- GLP-1 receptor agonists and their implications for female reproductive health.Case reports in women's health · 2026Article
- Fat reduction mediates the efficacy of intensive lifestyle interventions on fertility-sparing treatment in overweight patients with endometrial cancer and intraepithelial neoplasia.Acta obstetricia et gynecologica Scandinavica · 2026Article
- Effects of dyslipidemia on fertility-sparing treatment outcomes in endometrial atypical hyperplasia and endometrial cancer: a large cohort study.Scientific reports · 2026Article
- HIF1A, EPAS1, and VEGFA: angiogenesis and hypoxia-related gene expression in endometrium and endometrial epithelial tumors.Journal of applied genetics · 2026Article
- Pregnancy Outcomes Following Medical Therapy versus Levonorgestrel-Releasing Intrauterine System for Atypical Endometrial Hyperplasia.Therapeutics and clinical risk management · 2026Article
- Fertility-sparing treatment for overweight patients with early-stage endometrial cancer or atypical endometrial hyperplasia under weight loss intervention.Journal of cancer research and clinical oncology · 2025Article
- Obesity as a Catalyst for Endometrial Hyperplasia and Cancer Progression: A Narrative Review of Epidemiology, Molecular Pathways, and Prevention.Biomedicines · 2025Review
- Cancer of the corpus uteri: A 2025 update.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- Evidence-Based Weight Management for Fertility Preservation in Endometrial Cancer Patients: Developing a Complex Intervention Based on the Medical Research Council Framework.Healthcare (Basel, Switzerland) · 2025Article
- Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Weight Management for Fertility-Preservation Therapy in Endometrial Cancer: Opportunities and Challenges.Current oncology reports · 2025Review
- Global trends in the management of cancer through obesity reduction: a bibliometric based systematic literature review.Ecancermedicalscience · 2025Review
- Distribution and Related Influencing Factors of AMH Level in Family-Planning Women of Childbearing Age: A Cross-Sectional Study from Beijing, China.International journal of women's health · 2025Article
- Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer.Current oncology reports · 2024Review
- Review
- miRNA levels are associated with body mass index in endometrial cancer and may have implications for therapy.Cancer science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Intrauterine progestin is a treatment option for women with atypical hyperplasia or low-risk endometrial cancer who wish to preserve their fertility, or whose poor surgical fitness precludes safe hysterectomy. We hypothesized that in such women with obesity, weight loss during progestin treatment may improve oncological outcomes. We conducted a prospective nonrandomized study of women with obesity and atypical hyperplasia or low-grade stage 1a endometrial cancer undergoing progestin treatment. Women with a body mass index (BMI) ≥ 35 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.